Full Breakdown
Novo Nordisk Charts M&A and Diversification Strategy as Weight-Loss Drug Patents Near Expiry
By Drooid · · How we work
Core Event: CEO Outlines Acquisition-Focused Turnaround Plan
At a capital-markets presentation in London, Novo Nordisk chief executive Mike Doustdar said the Danish drugmaker is actively scouting merger-and-acquisition (M&A) opportunities to plug gaps in its weight-loss pipeline. He added that the firm intends to diversify its portfolio into adjacent therapeutic areas, including cardiovascular, liver and endocrine disorders, while continuing to pursue new obesity treatments.
Background & Context: Patent cliffs and rising competition
Novo’s flagship anti-obesity injection Wegovy and its diabetes medicine Ozempic both contain the GLP-1 ingredient semaglutide. Patent protection for these products is set to expire in the early 2030s in the United States and Europe, threatening a major revenue stream that currently represents roughly three-quarters of the company’s sales. U.S. rival Eli Lilly has expanded its GLP-1 lineup with Mounjaro, Zepbound and an oral pill, Foundayo, capturing a growing share of the market. Analysts note Lilly’s newer products are projected to outsell Wegovy by several billion dollars this year.
Data & Statistics
- Novo’s shares fell nearly 8% on the day of the event, the steepest single-day decline since February, and later traded modestly lower.
- Over the past 12 months the stock is down about 34%, while Lilly’s share price has risen roughly 54% in the same period.
- The company targets the launch of more than five “blockbuster” drugs by 2030 and expects pipeline sales of over 150 billion Danish crowns (about $23 billion) by 2035.
- Doustdar said Novo aims to reach more than 60 million patients worldwide by 2030 and to scale manufacturing tenfold to supply 15 million patients with oral obesity therapies by decade’s end.
- The oral Wegovy pill has already generated 7 million U.S. prescriptions, with about 90 % of sales occurring through cash-pay channels.
Official Statements & Responses
Doustdar described the diversification as “the right time now” to expand into therapeutic areas that are “not new to us,” and suggested future deals will focus on adjacent markets rather than core obesity assets. In a Bloomberg interview he acknowledged past “overpromising and underdelivering” and said investors now want clarity on the next steps.
Verbatim Quotes
- “Let's see where the gaps are, and let's go out and see who has produced or is about to introduce better drugs than we are able to do on our own, and when that gap can be filled with M&A, we are actually quite interested about it,” — Mike Doustdar, Novo CEO
- “I think yesterday we laid out a more clear strategy of the direction we want to take the company at. We talked about diversification of the company, but yet the reaction tells me that there's still some work to do in convincing some of the investors,” — Mike Doustdar, Novo CEO